Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.

Maria Pia GiannoccaroVeria VacchianoMarta LeoneFederico CamilliCorrado ZenesiniIvan PanzeraAlice BalboniMaria TappatàAnnamaria BorghiFabrizio SalviAlessandra LugaresiRita RinaldiGiulia Di FeliceVittorio LodiTiziana LazzarottoRocco Liguorinull null

Published in: Journal of neurology (2022)

SARS-CoV-2 mRNA vaccines were safe in a large group of ANC patients. Anti-CD20 and fingolimod treatment, as well as vaccination with the BNT162b2 vaccine, led to a reduced humoral response. These findings could inform vaccine policies in ANC patients undergoing immunotherapy.

Keyphrases

sars cov
immune response
patients undergoing
multiple sclerosis
end stage renal disease
newly diagnosed
respiratory syndrome coronavirus
ejection fraction
public health
chronic kidney disease
prognostic factors
peritoneal dialysis
binding protein
brain injury